If Obama Loves Children So Much Why is he selling Aborted Babies Are Being Chopped Up And Sold To Researchers All Over America

Tuesday, June 25, 2013 10:22

0

(Before It's News)

Aborted Babies Are Being Chopped Up And Sold To Researchers All Over America
http://www.infowars.com/aborted-babie…
If Obama loved children so much why is he selling aborted babys to be chopped up and sold for reseachers
Who can forget about  Obamas fake tears here at Sandyhook shootings  i got this video from you tube  please watch his video

http://www.youtube.com/user/newsreadallaboutit?feature=watch

With The Full Approval Of The Obama Administration
The American Dream
Tuesday, March 20, 2012
Did you know that aborted babies are being chopped up and sold to medical researchers all over America? There is a federal law which is supposed to ban this practice, but it contains a gigantic loophole that abortion clinics are using to sell huge amounts of aborted baby parts to the scientific community.
The loophole in the federal law allows “reasonable payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.” But there are no guidelines as to what those “reasonable payments” should be and the Obama administration is not about to start prosecuting abortion clinics. So aborted baby parts from American babies will continue to be very quietly sold for profit to medical researchers and most Americans will never hear anything about it. But future generations will look back in horror at what we allowed to be done right under our noses.
http://www.nomorefakenews.com/
http://www.infowars.com/
http://www.prisonplanet.tv/
https://twitter.com/#!/RealAlexJones
http://www.facebook.com/AlexanderEmer…

Aborted Babies Are Being Chopped Up And Sold To Researchers All Over America

With The Full Approval Of The Obama Administration
The American Dream
Tuesday, March 20, 2012
Did you know that aborted babies are being chopped up and sold to medical researchers all over America?  There is a federal law which is supposed to ban this practice, but it contains a gigantic loophole that abortion clinics are using to sell huge amounts of aborted baby parts to the scientific community.

The loophole in the federal law allows “reasonable payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.”  But there are no guidelines as to what those “reasonable payments” should be and the Obama administration is not about to start prosecuting abortion clinics.  So aborted baby parts from American babies will continue to be very quietly sold for profit to medical researchers and most Americans will never hear anything about it.  But future generations will look back in horror at what we allowed to be done right under our noses.
With the full approval of the Obama administration, one company in the United States has plans to inject aborted baby brain cells into the eyes of patients to see if that will help improve their vision.  The following is from a recent article onLifeNews.com….

Scott Fischbach, the director of Minnesota Citizens Concerned for Life uncovered the information showing a clinical trial approved by the Food and Drug Administration uses brain tissue from aborted unborn babies to treat macular degeneration. StemCells Inc. will inject fetal brain stem cells into the eyes of up to 16 patients to study the cells’ effect on vision.

As Fischbach correctly notes, a fetus must be at a certain stage of development before brain tissue can be harvested for this kind of research….

“StemCells Inc. is not using embryonic stem cells. A five-day-old human being at the embryonic stage does not have a brain, but a fetus at 10 or 20 weeks of development with visible fingers, toes and ears has a functioning brain,” said Fischbach. “Developing human beings in the womb are treated simply as raw material for laboratory experimentation by StemCells Inc. and other companies seeking to monetize aborted unborn children.”

But the harvesting of tissue and organs from aborted babies is definitely not new.  It has been going on for a long time.
For example, a recent article posted on worldmag.com describes the very big business that the Birth Defects Research Laboratory at the University of Washington in Seattle does in aborted baby parts….

It’s known within the research community as a top government distributor of fetal tissue. Last year the Puget Sound Business Journal stated the lab “in 2009 filled more than 4,400 requests for fetal tissue and cell lines.”
The lab’s grant records indicate it received $579,091 from the NIH last year. To date, it has retrieved the products of 22,000 pregnancies. According to a description the lab provided in its most recent grant applications, an increase in nonsurgical abortion methods has “created new obstacles to obtaining sufficient amounts of high quality tissue. To overcome these problems and meet increasing demand, the Laboratory has developed new relationships with both local and distant clinics.”

Once again, it is supposed to be against federal law to buy aborted baby parts from abortion clinics.  But this “problem” is avoided by taking advantage of the loophole that allows for “reasonable payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.”
An article posted on LifeDynamics.com describes how this system works….

1) A baby parts “wholesaler” enters into a financial agreement with an abortion clinic in which the wholesaler pays a monthly “site fee” to the clinic. For this payment, the wholesaler is allowed to place a retrieval agent inside the clinic where he or she is given access to the corpses of children killed there and a workspace to harvest their parts. In most cases, this retrieval agent is an employee of the wholesaler. In other instances, the retrieval agent is a clinic employee who was trained by the wholesaler.
2) The buyer – usually a researcher working for a medical school, pharmaceutical company, bio-tech company or government agency – supplies the wholesaler with a list of the baby parts wanted.
3) When such orders are received by the wholesaler, they are faxed to the retrieval agent at the clinic who harvests the requested parts and ships them to the buyer via FedEx, Airborne or a similar common carrier.
4) These parts are “donated” by the clinic to the wholesaler who turns around and “donates” them to the buyer. The buyer then “reimburses” the wholesaler for the cost of retrieving the parts.

In the end, nobody is technically “buying or selling” anything but they all get what they want and a lot of money changes hands.
A number of years ago an abortion industry insider came forward with shocking details of how this organ harvesting operation actually functions.  The following is from a very eye-opening InvestigateDaily article….

It was an interview that shocked America. An Insider, spilling the beans on massive malpractice to a reporter on ABC’s 20/20. Only this time, it wasn’t Big Tobacco in the gunsights, it was the US abortion industry, exposed as harvesting the organs from aborted babies. According to former abortion clinic technician Dean Alberty, clinics were harvesting eyes, brains, hearts, limbs, torsos and other body parts for sale to the scientific market: laboratories wanting to test new drugs or procedures, or researchers trying to find the causes of genetic disorders or discover new ways of treating disorders like Parkinsons.

Sometimes babies actually survive the initial abortion procedure and workers actually have to kill the babies themselvesbefore harvesting the organs….

Alberty worked for a Maryland agency called the Anatomic Gift Foundation, which essentially acted as a brokerage between universities and researchers seeking body parts, and the abortion clinics providing the raw material. Alerted by the clinics about the races and gestations of babies due to be aborted each day, AGF technicians would match the offerings with parts orders on their client lists. Alberty and his colleagues would turn up at the abortions that offered the best donor prospects to begin dissecting and extracting what they needed before decay set in.
“We would have a contract with an abortion clinic that would allow us to go in…[to] procure fetal tissue for research. We would get a generated list each day to tell us what tissue researchers, pharmaceuticals and universities were looking for. Then we would go and look at the particular patient charts—we had to screen out anyone who had STDs or fetal anomalies. These had to be the most perfect specimens we could give these researchers for the best value that we could sell for.
“We were taking eyes, livers, brains, thymuses, and especially cardiac blood…even blood from the limbs that we would get from the veins” he said.
Alberty told of seeing babies wounded but alive after abortion procedures, and in one case a set of twins “still moving on the table” when clinicians from AGF began dissecting the children to harvest their organs. The children, he said, were “cuddling each other” and “gasping for breath” when medics moved in for the kill.

You can read the rest of that shocking article right here.
So are you sick to your stomach yet?
This is a hard article to write, but the American people need to be confronted with the truth.  If we ignore the horrors going on right under our noses, then that would make us just like so many of the other nightmarish societies throughout history that we rightly condemn.
Sadly, most Americans don’t even realize that large numbers of consumer products on our supermarket shelves contain ingredients which have been cultivated using aborted human fetal cell lines.
This information is not hard to find.
But people do not like to talk about it.
There are price lists for human fetal tissue all over the Internet.  You can find one example right here.
So does it bother you that aborted babies are being chopped up and sold to researchers all over America?
Or are you perfectly fine with it?
Please feel free to leave a comment with your thoughts below….

Obama Admin OKs Using Aborted Babies’ Brains in Lab Tests

by Steven Ertelt | Washington, DC | LifeNews.com | 3/16/12 1:18 PM

• Print
• Email

National

•  
•  11.1K
•  
• Share

The Obama administration is getting grief from a pro-life group for approving an experiment using the remains of the bodies of unborn children victimized in abortion for research continues in U.S. laboratories.
Scott Fischbach, the director of Minnesota Citizens Concerned for Life uncovered the information showing a clinical trial approved by the Food and Drug Administration uses brain tissue from aborted unborn babies to treat macular degeneration. StemCells Inc. will inject fetal brain stem cells into the eyes of up to 16 patients to study the cells’ effect on vision.
In its press release announcing the clinical trial, StemCells Inc. was careful to refer to the fetal brain material as “purified human neural stem cell product” or HuCNS-SC cells, rather than “fresh human fetal brain tissue,” a description which can be found elsewhere on its website.
“StemCells Inc. is not using embryonic stem cells. A five-day-old human being at the embryonic stage does not have a brain, but a fetus at 10 or 20 weeks of development with visible fingers, toes and ears has a functioning brain,” said Fischbach. “Developing human beings in the womb are treated simply as raw material for laboratory experimentation by StemCells Inc. and other companies seeking to monetize aborted unborn children.”
In the press announcement, StemCells Inc. calls the use of the brains from babies killed in abortions “truly unique.”
“With the approval of this trial, we have accomplished something truly unique in the stem cell field, which is the extension of clinical testing of our proprietary human neural stem cell platform to all three elements of the central nervous system: the brain, spinal cord and eye,” said Martin McGlynn, President and CEO of StemCells, Inc. “The preclinical data supporting our IND is particularly compelling and we look forward to getting this trial underway.”
Fischbach said the dehumanization of nascent human life, applied to human embryos in order to justify the exploitation of embryonic stem cells, is now being applied to the harvesting of brain tissue from more developed unborn babies with functioning brains.
But he said the problem is not unique to StemCells Inc — pointing out that the misleadingly-named Birth Defects Research Laboratory at the University of Washington in Seattle is known within the research community as a top government distributor of fetal tissue.
The lab has been sponsored by the National Institutes of Health (NIH) for over four decades, according to a report in WORLD Magazine. The Puget Sound Business Journal stated that the lab “in 2009 filled more than 4,400 requests for fetal tissue and cell lines.” WORLD reports that the Seattle facility has retrieved the products of 22,000 pregnancies to date; the lab collects aborted fetuses from abortion centers across the country.
Experimental fetal stem cell treatments have yielded horrific results, he said.
Dr. David Prentice, an internationally recognized expert on stem cells and cloning, cites trials in which fetal stem cells have been used unsuccessfully to treat Parkinson’s disease. The New York Times called the outcome of a 2001 study “devastating” after “the patients writhed and jerked uncontrollably.” Another large clinical trial published in 2003 showed similar results.
“The use of morally illicit material in the biomedical industry violates the ‘do no harm’ principle that has governed the practice of medicine for millennia,” Fischbach said. “Adult stem cells offer the ethical and efficacious alternative. Unborn babies deserve dignity, not dissection and destruction.”
Locally, he said it is not known whether the University of Minnesota is experimenting with material from aborted fetuses, but it does use stem cells extracted from human embryos, which are killed in the process. Minnesota’s Human Conceptus Statute 145.422 prohibits the use of a living human conceptus for any type of research or experimentation.
“MCCL calls upon the U of M to pledge not to purchase or use fetal material in its research,” Fischbach added. “Such gruesome work violates human dignity and has no place in our state-funded institutions.”

News Release

View printer-friendly version

<< Back

StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial

NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company’s proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD.   AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD. “With the approval of this trial, we have accomplished something truly unique in the stem cell field, which is the extension of clinical testing of our proprietary human neural stem cell platform to all three elements of the central nervous system: the brain, spinal cord and eye,” said Martin McGlynn, President and CEO of StemCells, Inc. “The preclinical data supporting our IND is particularly compelling and we look forward to getting this trial underway.” The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina. Patients’ vision will be evaluated using conventional methods of ophthalmological assessment at predetermined intervals over a one-year period. Patients will then be followed for an additional four years in a separate observational study.  Preclinical data submitted as part of the Company’s Investigative New Drug application demonstrated that HuCNS-SC cells protect host photoreceptors and preserve vision in a well-established animal model of retinal disease that is relevant to dry AMD. HuCNS-SC transplants significantly protect against the degeneration of photoreceptors, the key cells of the eye involved in vision.  Moreover, the number of cone photoreceptors, which are responsible for central vision, remain constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed.  In humans, degeneration of the cone photoreceptors account for the unique pattern of visual loss in dry AMD.  A summary of the Company’s preclinical data was published in the February issue of the international peer-reviewed European Journal of Neuroscience, and is available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract. “We have published the preclinical evidence demonstrating that our human neural stem cells might offer a safe, effective and simple approach to treating AMD and other retinal diseases,” said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. ”Our approach is to provide durable protection of photoreceptors, thereby preserving vision, as opposed to approaches that aim to replace photoreceptors or the retinal pigmented epithelial cells. Furthermore, our preclinical data supports our hypothesis that we can achieve clinical benefit with a single transplant in AMD patients.” About StemCells, Inc. StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, and the Company expects to initiate a Phase I/II clinical trial in dry AMD in the near future.  In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer’s disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.   The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014 Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the prospect of the Company’s HuCNS-SC cells to preserve vision in animal models of retinal disease; the potential of the Company’s HuCNS-SC cells to treat a broad range of central nervous system disorders; the prospect and timing associated with initiating a clinical trial in a retinal disorder; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company’s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the results of the Company’s preclinical studies in retinal disease will be replicated in humans; uncertainty as to whether the FDA or other applicable regulatory agencies or review boards will permit the Company to continue clinical testing in spinal cord injury, PMD, AMD, or in future clinical trials of proposed therapies for other diseases or conditions given the novel and unproven nature of the Company’s technologies; uncertainties regarding the timing and duration of any clinical trials; uncertainties regarding the Company’s ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company’s ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, and in its subsequent reports on Forms 10-Q and 8-K. CONTACT: Rodney Young StemCells, Inc. Chief Financial Officer (510) 456-4128 David Pitts Argot Partners (212) 600-1902 Image: company logo StemCells, Inc.

Fetal attraction

Abortion | Aborted babies provide the vast majority of fetal tissue used in American medical research. Demand is high, competition for the tissue is strong, and oversight may be taking a back seat

Associated Press/Photo by Noah Berger

H. Ronald Zielke is a bank director. His institution collected $1.4 million in federal funds last year-but inside, you won’t find money. You’ll find human tissue.
Zielke’s bank is the Brain and Tissue Bank for Developmental Disorders, hosted by the University of Maryland School of Medicine. Each year it distributes some 3,000 tissue samples to researchers, collected from donors (average age: 20 to 40 years old) with neurological disorders ranging from autism to Down syndrome to Parkinson’s disease. The donors’ cellular material will aid researchers looking for treatments for such diseases.
According to the bank’s 234-page “Catalog of Available Tissue,” updated July 1, it also stores tissue from hundreds of fetuses, including those with chromosomal disorders, anencephaly (a brain malformation)-and many with no disorders at all, marked as “control” tissue and spanning ages 10 to 39 weeks.
I wanted to learn what scientists do with fetal tissue, and where they get it, so I called the bank director. The funny thing was, Zielke didn’t seem to know much about the source of fetal tissue. He thought researchers occasionally acquired fetal remains directly from “some service that does terminations,” such as clinics and hospitals with whom they had private agreements-but “this isn’t something that is generally known.”
When I asked Zielke if his bank distinguished between fetal tissue derived from abortions or miscarriages, he changed the subject: “There are very strict federal guidelines about how tissue can be collected,” he said, and alluded to the filing of consent forms. These types of questions, he insisted, were outside his expertise.
Federal and some state laws permit fetal tissue research, and although some regulation of the practice exists, there appear to be gaps in oversight. Few have firsthand knowledge of the secretive networks that procure the tissue, and no central agency or organization tracks them. But an uncomfortable reality is clear: The overwhelming majority of fetal tissue used for research in the United States is obtained from aborted babies.
Federal law prohibits the sale of fetal tissue for profit but allows “reasonable payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.” Such transactions were last in the media spotlight over a decade ago, when the pro-life organization Life Dynamics paid the employee of a fetal tissue collection organization to turn over evidence of legally questionable practices. (WORLD reported the news in October 1999 and April 2000.)
Life Dynamics uncovered confidential order forms and price lists showing that scientists at pharmaceutical companies and universities were ordering fetal parts-brains, limbs, and organs-from procurement groups that collected the tissue directly from abortion clinics. Life Dynamics said that one procurement group, the Maryland-based Anatomic Gift Foundation (AGF), made between $12,000 and $18,000 in profit during a single month.
Lawmakers called for a congressional hearing in March 2000, but when key witnesses failed to appear, and another witness proved unreliable, the matter stagnated and legislators dropped it. An FBI investigation later declared it had found no illegal activity.
Public attention was powerful, though: AGF dropped its fetal tissue business, and today the organization only accepts donors who are at least 18 years old. Two of the largest tissue suppliers in the country, who handled fetal tissue into the 1990s have also washed their hands of the trade. But that doesn’t mean the practice has ceased.
An assessment published in 1995 in The Journal of the American Medical Association concluded that fetuses obtained from miscarriages and ectopic pregnancies were a “quite limited” source for fetal tissue, while another study published in Clinical Orthopaedics and Related Research in 2001, the authors noted that out of 37 donated fetuses they used for their research, 33 had come from elective abortions. According to other journal articles, very little tissue comes from fetuses dying natural deaths.
To learn firsthand how tissue makes its way to research labs, I reached by phone the executive director of an abortion clinic that allows women to donate their fetuses. Jennifer Boulanger of the Allentown Women’s Center in Allentown, Pa., said her clinic supplies tissue to the University of Washington. She said her clinic is not paid for the donations, but the university provides her staff with the supplies needed to collect and ship the specimens.
In order to abide by state law, the clinic’s workers don’t tell women about the donation program until after they have made the decision to abort. Boulanger explained that although women must be a certain number of weeks along in their pregnancies to qualify for the program, “I would say the majority of those who are eligible choose to donate.”

The Marketing of Aborted Baby Parts by Mark Crutcher Original Release Date: February, 2000 Updated: March, 2007 In April of 1997, Life Dynamics began an undercover investigation into the marketing of body parts harvested from babies killed by elective abortions. This investigation lasted approximately 31 months. Most of the information in this report was provided by employees who worked at Comprehensive Health for Women (Comp Health) – a Planned Parenthood abortion clinic located in Overland Park, Kansas. The System Federal laws, and many state laws, make it illegal to buy or sell human bodies or body parts. However, they can be legally donated for medical research and certain other legitimate purposes. In such cases, the supplier is allowed to recover from the recipient any reasonable out-of-pocket expenses that were necessary to fill the recipient’s order. Some abortion industry insiders, wanting to financially profit on the growing market for fetal tissue and body parts, have devised a scheme to circumvent these restrictions. This is how the system works: 1) A baby parts “wholesaler” enters into a financial agreement with an abortion clinic in which the wholesaler pays a monthly “site fee” to the clinic. For this payment, the wholesaler is allowed to place a retrieval agent inside the clinic where he or she is given access to the corpses of children killed there and a workspace to harvest their parts. In most cases, this retrieval agent is an employee of the wholesaler. In other instances, the retrieval agent is a clinic employee who was trained by the wholesaler. 2) The buyer – usually a researcher working for a medical school, pharmaceutical company, bio-tech company or government agency – supplies the wholesaler with a list of the baby parts wanted. 3) When such orders are received by the wholesaler, they are faxed to the retrieval agent at the clinic who harvests the requested parts and ships them to the buyer via FedEx, Airborne or a similar common carrier. 4) These parts are “donated” by the clinic to the wholesaler who turns around and “donates” them to the buyer. The buyer then “reimburses” the wholesaler for the cost of retrieving the parts. On the surface, this system does not appear to violate the legal prohibitions against trafficking in human body parts since, technically speaking, no one is buying or selling anything. The loophole is that site fees and retrieval reimbursement amounts are unregulated. The law requires that such payments be reasonable and reflect the actual cost of securing the parts, but there are no state or federal laws which establish guidelines or sets limits regarding these payments. Additionally, no governmental or law enforcement agency is charged with overseeing the system. This means that the wholesaler is free to set site fees and retrieval fees at any amount. Despite the fact that the baby parts business is teeming with profound moral implications, and despite the fact it has enormous potential for financial abuse, it is allowed to operate on the honor system. It is certainly no secret that this sort of self-policing never works in environments where large amounts of money are involved. In this case, the result is that the corpses of children killed by elective abortion are now marketed like old car parts salvaged from the local junkyard. Rhetoric like “site fees,” “donations,” and “retrieval reimbursement costs” are simply code words designed to conceal that fact.